中国AI驱动的生物技术繁荣推进了基因治疗和药物开发,关键公司取得了重大的临床和技术里程碑。 China’s AI-driven biotech boom advances gene therapy and drug development, with key companies achieving major clinical and technological milestones.

人工智能正在推动中国基因治疗和药物开发取得重大进步,Insilico Medicine和METIS TechBio等公司率先进行创新。 Artificial intelligence is driving major advances in gene therapy and drug development in China, with companies like Insilico Medicine and METiS TechBio leading innovation. Insilico取得了第一种AI发现的药物,在第二阶段试验中显示出效果,而METIS针对肝脏和心脏等器官开发了AI设计的脂质纳米粒子。 Insilico achieved the first AI-discovered drug to show efficacy in a phase 2a trial, while METiS developed AI-designed lipid nanoparticles targeting organs like the liver and heart. 这些突破反映了中国在强大的投资、专利增长以及扩大与多国制药公司的全球伙伴关系的支持下,在可扩展的、可持续的AI驱动的生物技术领域发挥着日益重要的作用。 These breakthroughs reflect China’s growing role in scalable, sustainable AI-driven biotech, supported by strong investment, patent growth, and expanding global partnerships with multinational pharmaceutical firms.